Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Lactium, a proprietary casein-derived decapeptide (αS1-casein hydrolysate), is promoted for its calming and stress-reducing effects. Its potential use in supporting or treating hypertension is based on scientific evidence, though the strength of this evidence is moderate. Several clinical studies and animal experiments have suggested that bioactive peptides derived from milk proteins, including Lactium, can exert antihypertensive effects primarily through the inhibition of angiotensin-converting enzyme (ACE), a key enzyme involved in blood pressure regulation. By inhibiting ACE, these peptides may help reduce vasoconstriction and lower blood pressure.

One notable human study (Mizuno et al., 2004, European Journal of Clinical Nutrition) demonstrated a modest but statistically significant reduction in systolic and diastolic blood pressure in mildly hypertensive subjects after supplementation with a casein hydrolysate containing Lactium. Other studies have found similar results, though the blood pressure-lowering effect appears to be modest compared to established antihypertensive medications. The mechanism is thought to be similar to that of ACE-inhibitor drugs, though with a milder effect and fewer side effects.

Despite these findings, the overall body of evidence is still limited, with relatively small sample sizes and short intervention periods. Therefore, while there is scientific validation for the use of Lactium casein decapeptide in supporting blood pressure management, it should be considered as an adjunct rather than a replacement for standard hypertension therapies. Further large-scale, long-term studies are needed to confirm its efficacy and establish clinical guidelines.

More about lactium casein decapeptide
More about Hypertension

Other ingredients used for Hypertension

Other health conditions supported by lactium casein decapeptide

Products containing lactium casein decapeptide

Douglas Laboratories Sereniten Plus